Skip to main content
Clinical Trials/NCT03565263
NCT03565263
Completed
Not Applicable

Functional Gastrointestinal Disorders in Children and Adolescents With Inflammatory Bowel Disease in Remission: Prevalence and Identification of Clinical and Psychosocial Risk Factors

University Hospital, Caen1 site in 1 country350 target enrollmentApril 3, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Inflammatory Bowel Diseases
Sponsor
University Hospital, Caen
Enrollment
350
Locations
1
Primary Endpoint
Presence of Functional Gastrointestinal Disorder
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Background: Persistent gastrointestinal symptoms have been described in patients who are considered in remission of their inflammatory bowel disease (IBD). These symptoms, attributed to Functional gastrointestinal disorders (FGID) in IBD, may have a significant impact of quality of life, and may be associated with fatigue, anxiety and depression. There is very little data regarding pediatric specificities of these FGID.

Aims: The aim of the study is to evaluate the prevalence of FGID in pediatric patients with IBD in remission. Secondary aims are to investigate a possible association of FGID with fatigue, anxiety, depression and impacted quality of life in the patients, as well as anxiety and depression in the parents.

Methods: This will be an observational, case-control study. All patients between 9 and 18 years old , with IBD in remission will be invited to participate. Questionnaires will be web-based and will evaluate: presence of FGID (Fr-qPGS), fatigue (FACIT-F), anxiety (SCARED-R), depression (CDI), quality of life (IMPACT-III). Parents will be invited to fill in web-based questionnaires on their symptoms of anxiety (STAI/Y-A and STAI/Y-B) and depression (BDI). Clinical parameters will be retrieved retrospectively from the chart. Level of remission will be confirmed by most recent blood tests and fecal calprotectin. Patients with FGID will be compared to patients without FGID in terms of clinical characteristics, disease phenotype and associated psychological comorbidities.

Registry
clinicaltrials.gov
Start Date
April 3, 2018
End Date
November 8, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • IBD (Crohns disease, Ulcerative colitis or IBD-U)
  • in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, \< or = 3 stools/day, C reactive protein \< 10 mg/L, erythrocyte sedimentation rate \< 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy
  • followed for IBD for at least 1 year

Exclusion Criteria

  • presence of an ileostomy or colostomy
  • past history of total colectomy
  • unable to understand written French or to answer the questionnaires

Outcomes

Primary Outcomes

Presence of Functional Gastrointestinal Disorder

Time Frame: baseline

Rome III criteria for FGID (Fr-qPGS questionnaire)

Secondary Outcomes

  • Depression(baseline)
  • Depression (parents)(baseline)
  • Anxiety(baseline)
  • Quality of life - disease related(baseline)
  • Fatigue(baseline)
  • Anxiety (parents)(baseline)

Study Sites (1)

Loading locations...

Similar Trials